Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Food and Drug Administration drug insert for Campath (alemtuzumab)
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Antiinflammatory effects of orientin-2″-o-galactopyranoside on lipopolysaccharide-stimulated microglia.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
Gustatory Dysfunction in Multiple Sclerosis
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Roche's MabThera approved for two vasculitis indications in UK
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
Mitoxantrone for multiple sclerosis.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Ofatumumab Dose-finding in RRMS Patients
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.

Pages